Chengdu Easton Biopharmaceuticals Co Ltd (688513) — Net Asset Quality Index
Chengdu Easton Biopharmaceuticals Co Ltd (688513) has a Net Asset Quality Index of 81.7% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.78 Billion minus total liabilities of CN¥691.49 Million yields net assets of CN¥3.09 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Chengdu Easton Biopharmaceuticals Co Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Chengdu Easton Biopharmaceuticals Co Ltd Net Asset Quality Index Over Time (2013–2025)
This chart shows how Chengdu Easton Biopharmaceuticals Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 81.7%, representing net assets of CN¥3.09 Billion against total assets of CN¥3.78 Billion CNY. For live market cap and overall valuation, see 688513 company net worth.
Annual Net Asset Quality Index for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)
The table below presents the year-by-year Net Asset Quality Index for Chengdu Easton Biopharmaceuticals Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See Chengdu Easton Biopharmaceuticals Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 175.5% | CN¥6.66 Billion | CN¥3.80 Billion | CN¥-2.87 Billion | ▲ +96.1 pp |
| 2024 | 79.3% | CN¥2.70 Billion | CN¥3.40 Billion | CN¥702.21 Million | ▲ +1.6 pp |
| 2023 | 77.8% | CN¥2.60 Billion | CN¥3.35 Billion | CN¥743.33 Million | ▼ -3.2 pp |
| 2022 | 81.0% | CN¥2.44 Billion | CN¥3.02 Billion | CN¥573.08 Million | ▼ -1.6 pp |
| 2021 | 82.6% | CN¥2.29 Billion | CN¥2.78 Billion | CN¥483.60 Million | ▼ -0.2 pp |
| 2020 | 82.8% | CN¥2.10 Billion | CN¥2.53 Billion | CN¥435.61 Million | ▲ +12.1 pp |
| 2019 | 70.7% | CN¥697.44 Million | CN¥987.08 Million | CN¥289.64 Million | ▼ -3.1 pp |
| 2018 | 73.7% | CN¥582.19 Million | CN¥789.69 Million | CN¥207.50 Million | ▼ -1.5 pp |
| 2017 | 75.2% | CN¥445.28 Million | CN¥591.98 Million | CN¥146.70 Million | ▲ +0.3 pp |
| 2016 | 74.9% | CN¥389.79 Million | CN¥520.22 Million | CN¥130.43 Million | ▼ -11.1 pp |
| 2015 | 86.1% | CN¥268.21 Million | CN¥311.63 Million | CN¥43.42 Million | ▲ +14.3 pp |
| 2014 | 71.8% | CN¥203.25 Million | CN¥283.10 Million | CN¥79.85 Million | ▲ +5.6 pp |
| 2013 | 66.2% | CN¥168.62 Million | CN¥254.86 Million | CN¥86.24 Million | — |